Indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound and use thereof
Summary
USPTO granted patent US12590093B2 to the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, covering an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound for treating cardiovascular and cerebrovascular diseases. The patent lists 13 inventors and contains 4 claims, with applications including increasing expression of AMPK, ABCA1, and SR-BI, and inhibiting NLRP3, IL-1β, NF-κB, and MAPKs.
What changed
USPTO issued Patent No. US12590093B2 to the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, for an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound (general formula I). The patent covers use in manufacturing medicaments for treating cardiovascular/cerebrovascular diseases, formulations for increasing expression of AMPK, ABCA1, and SR-BI, and anti-inflammatory applications. The patent was granted March 31, 2026, with Application No. 17767218 filed September 27, 2020.
This patent grant establishes intellectual property rights for the Chinese Academy of Medical Sciences. Pharmaceutical companies developing cardiovascular treatments should conduct freedom-to-operate analyses to ensure their compounds or methods do not infringe this patent. Companies with overlapping cardiovascular drug pipelines should review this patent landscape to assess potential licensing needs or design-around strategies.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound and use thereof
Grant US12590093B2 Kind: B2 Mar 31, 2026
Assignee
INSTITUTE OF MEDICINAL BIOTECHNOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES
Inventors
Shuyi Si, Yanni Xu, Xiao Wang, Jinque Luo, Yongzhen Li, Chao Liu, Xinhai Jiang, Yining Li, Xiaowan Han, Yan Li, Minghua Chen, Jing Zhang, Xin Zhen
Abstract
The disclosure relates to an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound represented by general formula (I) and use thereof in the manufacture of (1) a medicament for treating a cardiovascular and cerebrovascular disease, (2) a formulation for increasing expression of AMPK, ABCA1 and SR-BI, (3) a formulation for activating nuclear receptors (NRs), and inhibiting activity of NLRP3, IL-1β, NF-κB and MAPKs, (4) a formulation for promoting cellular cholesterol efflux; or (5) a medicament for anti-inflammation.
CPC Classifications
C07D 471/14 C07D 471/22 C07D 498/14 A61P 9/10 A61P 3/06 A61P 29/00
Filing Date
2020-09-27
Application No.
17767218
Claims
4
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.